NasdaqGM:PTGXBiotechs
A Valuation Check on Protagonist Therapeutics (PTGX) After Sharply Widened Quarterly Losses
Protagonist Therapeutics (PTGX) posted its third-quarter earnings, showing a shift to a higher net loss compared to last year. The company also moved from net income to net loss for the nine months ended September 30.
See our latest analysis for Protagonist Therapeutics.
Despite shifting to a deeper net loss in the latest earnings, Protagonist Therapeutics' share price has surged 117% year to date, with a strong one year total shareholder return of 109%. This impressive momentum hints at...